Akero Therapeutics Inc

Akero Therapeutics — Investor Presentation (June 2022)

45 slides from Akero Therapeutics's investor presentation, Jun 8, 2022

  1. Slide 1: Restoring Balance. Renewing Life. Corporate Presentation June 2022

    Exhibit 99.1 Restoring Balance. Renewing Life. Corporate Presentation June 2022

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but no

  3. Slide 3: Corporate Highlights

    Corporate Highlights 1 2 3 Potential First-in-Class Building Momentum Toward Experienced Team with & Best-in-Class NASH Drug Phase 3 Pivotal Trials Strong Cash Position • Substantial potential market • Two parallel Phase 2b trials underway • Involved in 20+ FDA approvals opportunity • HARMONY (F2-F3

  4. Slide 4: Extensive Development and Commercialization Experience

    Extensive Development and Commercialization Experience Involved in 20+ Medicine Approvals Andrew Cheng, MD, PhD | President & CEO • 19 years at Gilead • Chief Medical Officer & HIV Division Head • Major role in 11 NDA/MAA approvals Tim Rolph, D.Phil | Co-Founder & Chief Scientific Officer Kitty Yale

  5. Slide 5: Providing a Potentially Effective Treatment for NASH

    Providing a Potentially Effective Treatment for NASH Reducing liver fat Achieving >10% weight is critical to remove loss is challenging for disease driver patients who are obese Peripheral fat Insulin resistance and is the largest source of Type 2 Diabetes drives liver fat in patients with liver cal

  6. Slide 6: EFX Engineering Potentially Optimal for NASH Efficacy, With Convenient Once-weekly Dosing

    EFX Engineering Potentially Optimal for NASH Efficacy, With Convenient Once-weekly Dosing Key attributes Akero proprietary Increases half-life High affinity for Fc-FGF21, from < 2 hours β-Klotho Point mutations to 3-4 days Better translation Balanced potency Inactive to human at FGFR1c, 2c, 3c at FG

  7. Slide 7: EFX Acts on Two Major Sources of Liver Fat

    EFX Acts on Two Major Sources of Liver Fat With Potential for Optimal Reduction Sources of Fat Flowing into and Acting on both hepatic and peripheral sources of liver Through Liver for Patients with NASH fat is key to optimizing liver fat reduction Dietary Fat Source of Liver Fat FGF Receptor EFX Ac

  8. Slide 8: EFX Direct And Indirect Anti-fibrotic Effects

    EFX Direct And Indirect Anti-fibrotic Effects Pathogenesis of Fibrosis Hepatocyte Stress & Death Kupffer Cell Activation Myofibroblast Differentiation Fibrogenesis EFX Anti-Fibrotic Activity Bao, L et al. (2018) Br J Pharmacol 175:3379-3393; Fisher, FM et al. (2014) Gastroenterology 147:1073-1083.e6

  9. Slide 9: Phase 2a Trial (Balanced) Design (F1-F3)

    Phase 2a Trial (Balanced) Design (F1-F3) 16 WEEKS Primary Endpoint • Absolute Liver Fat Placebo (n=20) Key Secondary Endpoints • Relative Liver Fat 28mg EFX (n=20) • Response Rate • ALT 50mg EFX (n=20) Key Exploratory Efficacy Endpoints • 2-Point NAS Improvement • Fibrosis Improvement • NASH Resolut

  10. Slide 10: Phase 2a Expansion Cohort C Trial Design (F4)

    Phase 2a Expansion Cohort C Trial Design (F4) BALANCED study included an expansion cohort, Cohort C, of patients with compensated cirrhosis (F4), Child-Pugh Class A 16 WEEKS Primary Endpoint Safety & tolerability Placebo (n=10) EFX 50 mg (n=20) * Liver Biopsy * Protocol amended to include voluntary

  11. Slide 11: Baseline Demographics: Main Study & Cohort C

    Baseline Demographics: Main Study & Cohort C a b BALANCED Main Study Cohort C Placebo EFX 28mg EFX 50mg EFX 70mg Placebo EFX 50mg Parameter Mean (N=21) (N=19) (N=20) (N=20) (N=10) (N=20) Age (Years) 52 50 53 53 57.1 61.1 Sex (Male/Female) 6/15 9/10 10/10 9/11 7/3 4/16 Weight (kg) 99.6 108.2 103.6 10

  12. Slide 12: Substantial Reductions in Liver Fat Across All Dose Groups (F1-F3 NASH)

    Substantial Reductions in Liver Fat at Week 12 Across All Dose Groups (F1-F3 NASH) Proportion of Patients Achieving Fat Reduction Thresholds LS Mean Reduction in Liver Fat Placebo 28mg 50mg 70mg Placebo 28mg 50mg 70mg Endpoint Placebo 28mg 50mg 70mg (N=20) (N=16) (N=17) (N=15) 0 -0% Relative Reducti

  13. Slide 13: High Rates of Fibrosis Improvement Across All Dose Groups (F1-F3 NASH)

    High Rates of Fibrosis Improvement After 16 Weeks Across All Dose Groups (F1-F3 NASH) Fibrosis Improvement ≥1 Stage and 1,2 No Worsening of NASH 70% 70% 62% Biopsy Reading 60% 60% • All baseline and end-of-treatment 48% 50% 50% 46% biopsies were centrally read by a single NASH-CRN pathologist 40% 40

  14. Slide 14: EFX F1-F3 Fibrosis Improvement in Context

    EFX F1-F3 Fibrosis Improvement in Context 1 Proportion of Patients with ≥1 Stage Improvement in Fibrosis and No Worsening of NASH Fc-FGF21 GlycoPEG-FGF21 PPAR Thyroid β GLP-1 Madrigal Akero Inventiva Madrigal Novo Nordisk Efruxifermin Pegozafermin Lanifibranor Resmetirom Semaglutide Weekly Injection

  15. Slide 15: Half of F2-F3 EFX Patients Achieved 2-Stage Fibrosis Improvement

    Half of F2-F3 EFX Patients Achieved 2-Stage Fibrosis Improvement Fibrosis Change in EFX-Treated Patients Fibrosis Change in EFX-Treated Patients with Baseline F1-F3 Fibrosis (n=40) with Baseline F2 or F3 Fibrosis (n=22) 2-Stage 28% Improvement (n=11) 2-Stage 50% 55% Improvement (n=11) 68% 1-Stage 28

  16. Slide 16: Rapid Improvements in Fibrosis Biomarkers Consistent with Histological Improvements

    Rapid Improvements in Fibrosis Biomarkers Consistent with Histological Improvements (F1-F3 NASH) Pro-C3, LS Mean (ug/L) Pro-C3, LS Mean Change from Baseline Dose Group Baseline Δ Week 12 BL W1 W4 W8 W12 Placebo 16.1 -1.5 10% *** 19.2 -6.1 28mg *** 16.2 -5.9 0% 50mg *** 70mg 17.2 -6.7 -10% -20% Enhan

  17. Slide 17: Improved Lipoprotein Profile (F1-F3 NASH)

    Improved Lipoprotein Profile (F1-F3 NASH) LS Mean Change From Baseline to Week 16 (%) Triglycerides HDL Cholesterol Non-HDL Cholesterol LDL Cholesterol 10% 50% 0% 0% -2% 0% -1% +6% *** 0% 40% *** -5% -5% -6% +41% *** +39% -10% 30% -10% +34% -15% -10% -20% 20% -15% -17% * -30% -16% -39% ** -15% -22%

  18. Slide 18: High Response Rates on NASH Resolution Across All Dose Groups

    High Response Rates on NASH Resolution After 16 Weeks Across All Dose Groups (F1-F3 NASH) 1,2 NASH Resolution and No Worsening of Fibrosis 70% 70% 60% 60% 54% 50% 48% 50% 50% 46% 43% 40% 40% 30% 30% * 1 19 6 7 6 20% 20% 10% 10% 0% 0% Overall Overall Placebo All EFX 28mg 50mg 70mg N=2 N=40 N=13 N=13

  19. Slide 19: Substantial Reductions in Markers of Liver Injury

    Substantial Reductions in Markers of Liver Injury After 16 Weeks of Treatment (F1-F3 NASH) ALT, LS Mean Change from Baseline AST, LS Mean Change from Baseline BL W1 W4 W8 W12 W16 W20 BL W1 W4 W8 W12 W16 W20 40% 40% 20% 20% 0% 0% *** -20% -20% ** *** ** *** *** *** *** *** *** *** *** *** *** *** ***

  20. Slide 20: Clinically Meaningful Improvements in Glycemic Control After 16 Weeks

    Clinically Meaningful Improvements in Glycemic Control After 16 Weeks (F1-F3 NASH) LS Mean Change From Baseline to Week 16 (%) 1 2 HbA1c C-Peptide All Patients (N=80) Patients with Type 2 DM (N=41) All Patients (N=80) Patients Type 2 DM (N=41) 0.1 0.2 20% 20% +21% +0.1 0.1 0.0 +0.0 -0.1 +0.1 0.0 -0.

  21. Slide 21: Weight Loss Observed For All Dose Groups (F1-F3 NASH)

    Weight Loss Observed For All Dose Groups (F1-F3 NASH) Mean Change in Body Weight (kg) Mean Change in Body Weight at Week 16 (kg) BL W1 W4 W8 W12 W16 0 +0.1 0 -0.3 -1 -1 -2 -2.3 -2 -3 -3 -3.7 -4 -4 W16 Placebo 28mg 50mg 70mg Placebo 28mg 50mg 70mg Source Data: Full Analysis Set, F1-F3 ©2022 AKERO THE

  22. Slide 22: Consistent Results Observed for Relevant Endpoints (F1-F3)

    Consistent Results Observed for Relevant Endpoints (F1-F3) b b a Fibrosis Change in Patients HbA1c, % C-Peptide (%) Liver Fat (%) d,e,f with F2 or F3 at Baseline Placebo EFX 28mg EFX 50mg Placebo EFX 28mg EFX 50mg Placebo EFX 28mg EFX 50mg Pbo 28mg 50mg Pbo 28mg 50mg Pbo 28mg 50mg 0% 2-Stage +0.1 50

  23. Slide 23: Drug-related Treatment-Emergent Adverse Events (TEAE) (F1-F3)

    Drug-related Treatment-Emergent Adverse Events (TEAE) (F1-F3) Most Frequent (>10%) Placebo All EFX EFX 28mg EFX 50mg EFX 70mg * (N=21) (N=58) (N=19) (N=19) (N=20) Drug-Related AEs Diarrhea 2 (10%) 21 (36%) 5 (26%) 10 (53%) 6 (30%) Nausea 0 (0%) 20 (34%) 6 (32%) 4 (21%) 9 (45%) Increased appetite 1 (

  24. Slide 24: Value of Preventing Progression to & Reversing From Cirrhosis

    Value of Preventing Progression to & Reversing From Cirrhosis Survival Free of Liver Transplantation 100% 80% F0 ~50% 60% 5-year mortality 50% F1 without liver transplant 40% F2 for F4 patients F3 20% F4 P<0.001 0% Follow-up (years) Angulo, P et al. (2015) Gastroenterology 149:389-397 ©2022 AKERO TH

  25. Slide 25: Cirrhosis Regression is Associated with Improved Clinical Outcomes

    Cirrhosis Regression is Associated with Improved Clinical Outcomes Pooled treatment groups from STELLAR 4 and simtuzumab cirrhosis study Hazard Ratio: 0.16 Hazard Ratio: 0.08 p=0.0104 p=0.0004 9 8.3 8 7.2 7 No fibrosis regression 6 Fibrosis regression 5 4 3 2 1.1 0.7 1 2/176 69/957 69/834 2/300 0 NA

  26. Slide 26: Fibrosis Improvement in Pre-cirrhotic (F1-F3) and Compensated Cirrhotic (F4) NASH

    Fibrosis Improvement Observed in Patients with Pre-cirrhotic (F1-F3) and Compensated Cirrhotic (F4) NASH Fibrosis Improvement 1,2 Improvement ≥1 Stage and No Worsening of NASH F1-F3 F4 70% 70% 60% 60% 62% 50% 50% 40% 40% 30% 30% 33% 20% 20% 10% 10% 0% 0% 0% 0% Placebo EFX 50mg Pb Plac oebo EF 5 X 5

  27. Slide 27: EFX F4 Fibrosis Improvement in Context

    EFX F4 Fibrosis Improvement in Context FGF21 ASK-1 ACC FXR GAL-3 LOXL2 Belapectin Efruxifermin Selonsertib Firsocostat Cilofexor Simtuzumab 40 48 Wks 48 Wks 48 Wks 52 Wks 96 Wks Increasing 16 Wks dosing 33% duration 30 20 16% 15% 14% 14% 14% 13% 13% 13% 10 8% 8% 7% 5% 0% 2% 0 Pbo EFX 50mg Pbo 6mg 18

  28. Slide 28: Improvement in Lipid Profile Observed in F1-F3 and F4 NASH

    Improvement in Lipid Profile Observed in Patients with both Pre- cirrhotic (F1-F3) and Compensated Cirrhotic (F4) NASH Non-HDL Cholesterol (%) Triglycerides (%) HDL Cholesterol (%) LS Mean Change From Baseline at Week 16 (%) LS Mean Change From Baseline at Week 16 (%) LS Mean Change From Baseline at

  29. Slide 29: Improved Glycemic Control Observed in F1-F3 and F4 NASH

    Improved Glycemic Control Observed in Patients with both Pre- cirrhotic (F1-F3) and Compensated Cirrhotic (F4) NASH HbA1c, % C-peptide (%) LS Mean Change From Baseline at Week 16 (%) LS Mean Change From Baseline at Week 16 (%) F1-F3 F4 F1-F3 F4 Placebo EFX 50mg Pbo 50mg Pbo 50mg Placebo EFX 50mg Pla

  30. Slide 30: Weight Loss Observed in F1-F3 and F4 NASH

    Weight Loss Observed in Patients with both Pre-cirrhotic (F1-F3) and Compensated Cirrhotic (F4) NASH Body Weight LS Mean Change From Baseline at Week 16 (Kg) F1-F3 F4 1.5 1.5 1.0 1.0 +1.2 0.5 0.5 +0.5 0.0 0.0 -0.5 -0.5 -1.0 -1.0 -1.7 -1.5 -1.5 -2.2 -2.0 -2.0 -2.5 -2.5 Placebo EFX 50mg Placebo EFX 50

  31. Slide 31: Interpreting the Rapid Reversal of Fibrosis Observed in EFX-treated Patients

    Interpreting the Rapid Reversal of Fibrosis Observed in EFX-treated Patients with NASH ↓ Inflammation ↓ Liver fat ↓ Collagen Synthesis ↓ Hepatocyte Stress Directly anti-fibrotic Indirectly anti-fibrotic EFX • Fibrosis reversal in patients with compensated cirrhosis (F4), • Addressing underlying NASH

  32. Slide 32: EFX Positioning as Potential Best-in-Class NASH Therapy

    EFX Positioning as Potential Best-in-Class NASH Therapy Liver Fat Reduction Consistent Fibrosis Reversal Activity NASH Resolution Reduced Cardiovascular Risk EFX+ F2-F4 Restored Healthy Lipid Profile Enhanced Insulin Sensitivity Better Glycemic Control Monotherapy Weight Loss ©2022 AKERO THERAPEUTIC

  33. Slide 33: Building Foundation for Phase 3: Parallel Phase 2b Trials

    Building Foundation for Phase 3: Parallel Phase 2b Trials Phase 2a Phase 2b F1-F3 F4 F2/F3 F4 Biopsy-Confirmed: Cohort C BALANCED HARMONY SYMMETRY (Expansion of BALANCED) Enrollment complete; Status Completed Completed Readout expected Initiated Jul’21 in 3Q’22 Duration 16 Weeks 16 Weeks 24 Weeks 36

  34. Slide 34: HARMONY Trial Design: Non-Cirrhotic NASH (F2/F3)

    HARMONY Trial Design: Non-Cirrhotic NASH (F2/F3) Key Inclusion Criteria Key Secondary Efficacy Endpoints Phase 2b Primary Endpoint • F2-3 NASH • Fibrosis Improvement • NASH Resolution • Weight Change • NAS ≥4 • Fibrosis Markers • MRI-PDFF • Liver fat ≥8% • Lipoproteins • Liver Injury Markers • Glyce

  35. Slide 35: SYMMETRY Trial Design: Cirrhosis Due to NASH (F4)

    SYMMETRY Trial Design: Cirrhosis Due to NASH (F4) Key Inclusion Criteria Key Secondary Efficacy Endpoints Phase 2b Primary Endpoint • F4 NASH • Fibrosis Improvement • NASH Resolution • Glycemic Control (Cirrhosis reversal) • Fibrosis Markers • Weight Change • Lipoproteins • Liver Injury Markers Long

  36. Slide 36: Histopathology Scoring of Biopsies in HARMONY and SYMMETRY

    No Paired Reads • Shuffled Slide Sequence Histopathology Scoring of Biopsies in HARMONY and SYMMETRY Key Features of EFX Biopsy Analysis Plan Biopsy Analysis Flow Chart • Incorporates FDA input on EFX Phase 2b trial designs, Slides Prepared From Tissue Samples reflecting efforts to increase liver bi

  37. Slide 37: Evaluating EFX for Potential Use with GLP-1 Receptor Agonists

    Evaluating EFX for Potential Use with GLP-1 Receptor Agonists Cohort D Design: Non-Cirrhotic NASH (F1-F3) 12 WEEKS Primary Endpoint • Safety & Tolerability GLP-1 Receptor Agonist + Placebo (n=10) Secondary Endpoints Key Inclusion Criteria • HbA1c • HbA1c ≥ 7.0% and ≤10.5% • Fibrosis Markers • Stable

  38. Slide 38: Supplying API and Drug Product/Device for Phase 3

    Supplying API and Drug Product/Device for Phase 3 Drug Substance (API) Drug Product/Device Combination Commercial scale Commercially precedented Released for Phase 3 1 mL SC weekly injection Comparability demonstrated Self-administered, stable at 2-8ºC ©2022 AKERO THERAPEUTICS. 38

  39. Slide 39: Strong Financial Position

    Strong Financial Position 1 COMPLETED COMPLETED UPSIZED CASH UPSIZED IPO ON HAND FOLLOW-ON OFFERING June 20, 2019 As of March 31, 2022 June 10, 2020 ~$ ~$ 106M 216M ~$ 165M Raised in aggregate Raised in aggregate gross proceeds gross proceeds 1 Priced upsized IPO at top of Priced upsized follow-on o

  40. Slide 40: Backup Slides

    ak=ro Backup Slides

  41. Slide 41: Patient Disposition (Balanced Main Study)

    Patient Disposition (Balanced Main Study) Randomized (80) Randomized Not Dosed EFX (1) Dosed (79) Discontinued (11) Administrative Due to AEs EFX (4) EFX (6) - Pbo (1) Week 12 MRI-PDFF (68) Non-Responders Placebo (18) MRI-PDFF Responders (50) (≥ 30% Relative Reduction) Biopsies Not Collected Due to

  42. Slide 42: Improvements in Fibrosis Biomarkers in Patients with Cirrhotic NASH (F4)

    Improvements in Fibrosis Biomarkers in Patients with Cirrhotic NASH Support Histology Results (F4) LS Mean Change From Baseline to Week 16 1 Liver Stiffness (kPa) Pro-C3 (µg/L) ELF Score 0 0 0.3 +0.3 0.2 -1 -2 -1.9 -3.4 0.1 -2 -4 0.0 -3 -0.1 -6 -4 -0.2 * -9.0 -8 †† -5 -5.7 -0.3 ** -0.4 -6 -10 -0.4 C

  43. Slide 43: Tolerability Overview (F4)

    Tolerability Overview (F4) Most Frequent (>15%) Placebo EFX 50mg Drug-Related AEs (N=10) (N=17) Key Observations Diarrhea 1 (10%) 7 (41%) • Encouraging tolerability given population with more advanced Nausea 1 (10%) 5 (29%) disease Injection site reaction 0 5 (29%) • All injection site AEs Grade 1 I

  44. Slide 44: NASH Resolution Also Observed in Patients with Cirrhotic NASH (F4)

    NASH Resolution Also Observed in Patients with Cirrhotic NASH (F4) 1,2 NASH Resolution 30% Change in NAS among Patients Achieving NASH Resolution 25% EFX Subject Baseline NAS Week 16 NAS 20% A 7 1 B 3 1 C 6 1 3 10% Proportion of Patients with ≥2 Point NAS Reduction Placebo EFX 50mg 0% 0% 1 (20%) 7 (

  45. Slide 45: Akero Therapeutics

    AKERO THERAPEUTICS 601 Gateway Boulevard NASDAQ: AKRO Suite 350 South San Francisco, CA 94080

Akero Therapeutics — Investor Presentation (June 2022) on 6ix